Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chimera Antigen Receptor (CAR)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT03241940
What this trial is testing

Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies

Who this might be right for
B Acute Lymphoblastic LeukemiaCD19 PositiveMinimal Residual Disease+4 more
Stanford University 33
Early research (Phase 1)UnknownNCT03086954
What this trial is testing

Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma

Who this might be right for
Lymphoma
Sinobioway Cell Therapy Co., Ltd. 24
Early research (Phase 1)Looking for participantsNCT06198296
What this trial is testing

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells

Who this might be right for
HepatoblastomaHepatocellular CarcinomaWilms Tumor+5 more
Baylor College of Medicine 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05091541
What this trial is testing

CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Who this might be right for
B-cell Non-Hodgkin's Lymphoma
Nanjing IASO Biotechnology Co., Ltd. 125
Early research (Phase 1)Looking for participantsNCT07179692
What this trial is testing

CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

Who this might be right for
Lung CancerGastric CancerColon Cancer+3 more
Chongqing Precision Biotech Co., Ltd 108
Early research (Phase 1)Active Not RecruitingNCT00902044
What this trial is testing

Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma

Who this might be right for
Sarcoma
Baylor College of Medicine 36
Testing effectiveness (Phase 2)Looking for participantsNCT05850234
What this trial is testing

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AstraZeneca 232
Early research (Phase 1)Looking for participantsNCT07751380
What this trial is testing

Multi-modular Chimeric Antigen Receptor T Cells tarGeting B7-H3 in Children, Teenage & Young Adult Sarcoma

Who this might be right for
Sarcoma
University College, London 12
Very early researchNot Yet RecruitingNCT07458659
What this trial is testing

Clinical Study of BCMA-Targeted CAR T-Cell Injection in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (MM)
Chulalongkorn University 3
Not applicableLooking for participantsNCT06607289
What this trial is testing

National Longitudinal Cohort of Hematological Diseases (NICHE) - CART

Who this might be right for
Hematological Malignancies
Institute of Hematology & Blood Diseases Hospital, China 1,000
Very early researchLooking for participantsNCT06756321
What this trial is testing

CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

Who this might be right for
Relapsed/refractory LymphomaRelapsed/Refractory Leukemia
Affiliated Hospital of Nantong University 9
Early research (Phase 1)Looking for participantsNCT07078929
What this trial is testing

Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Relapse B Acute Lymphoblastic LeukemiaRefactory Childhood Acute Lymphoblastic Leukemia
Chulalongkorn University 16
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07503353
What this trial is testing

T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

Who this might be right for
B Cell MalignanciesAcute Lymphobkastic LeukemiaNon-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)
Sheba Medical Center 50
Testing effectiveness (Phase 2)Ended earlyNCT03954106
What this trial is testing

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

Who this might be right for
DLBCLNeurotoxicity Syndromes
Jazz Pharmaceuticals 25
Testing effectiveness (Phase 2)UnknownNCT05651100
What this trial is testing

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Kecellitics Biotech Company Ltd 50
Very early researchNot Yet RecruitingNCT06359509
What this trial is testing

Study of SYS6020 in BCMA-positive Multiple Myeloma

Who this might be right for
Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 10
Early research (Phase 1)Study completedNCT02905188
What this trial is testing

Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)

Who this might be right for
Hepatocellular Carcinoma
Baylor College of Medicine 9
Testing effectiveness (Phase 2)UnknownNCT02644655
What this trial is testing

Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia

Who this might be right for
Recurrent B-Cell TumorRefractory B-Cell Tumor
Second Military Medical University 20
Testing effectiveness (Phase 2)Temporarily pausedNCT05138458
What this trial is testing

MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Who this might be right for
Lymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousMycosis Fungoides+2 more
Myeloid Therapeutics 40
Testing effectiveness (Phase 2)Looking for participantsNCT05326243
What this trial is testing

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaLarge B-cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd. 49
Next Page